1
|
Chourey S, Wang R, Ye Q, Reddy CN, Sun S, Takenaka N, Powell WS, Rokach J. Concise Syntheses of Microsomal Metabolites of a Potent OXE (Oxoeicosanoid) Receptor Antagonist. Chem Pharm Bull (Tokyo) 2023; 71:534-544. [PMID: 37394602 DOI: 10.1248/cpb.c22-00926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/04/2023]
Abstract
5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is the most potent eosinophil chemoattractant among lipid mediators, and its actions are mediated by the selective oxoeicosanoid (OXE) receptor. Our group previously developed a highly potent indole-based OXE antagonist, S-C025, with an IC50 value of 120 pM. S-C025 was converted to a number of metabolites in the presence of monkey liver microsomes. Complete chemical syntheses of authentic standards enabled us to identify that the four major metabolites were derived by the oxidation at its benzylic and N-methyl carbon atoms. Herein we report concise syntheses of the four major metabolites of S-C025.
Collapse
Affiliation(s)
- Shishir Chourey
- Claude Pepper Institute and Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| | - Rui Wang
- Claude Pepper Institute and Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| | - Qiuji Ye
- Claude Pepper Institute and Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| | - Chintam Nagendra Reddy
- Claude Pepper Institute and Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| | - Shiyu Sun
- Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| | - Norito Takenaka
- Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| | - William S Powell
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre
| | - Joshua Rokach
- Claude Pepper Institute and Department of Biomedical and Chemical Engineering and Sciences, Florida Institute of Technology
| |
Collapse
|
2
|
Cossette C, Chourey S, Ye Q, Reddy CN, Wang R, Poulet S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Metabolism of anti-inflammatory OXE (oxoeicosanoid) receptor antagonists by nonhuman primates. Eur J Pharm Sci 2022; 172:106144. [DOI: 10.1016/j.ejps.2022.106144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 01/21/2022] [Accepted: 02/10/2022] [Indexed: 11/28/2022]
|
3
|
Powell WS, Rokach J. Targeting the OXE receptor as a potential novel therapy for asthma. Biochem Pharmacol 2020; 179:113930. [PMID: 32240653 PMCID: PMC10656995 DOI: 10.1016/j.bcp.2020.113930] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Accepted: 03/19/2020] [Indexed: 12/11/2022]
Abstract
5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is an arachidonic acid metabolite formed by oxidation of the 5-lipoxygenase (5-LO) product 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5S-HETE) by the NADP+-dependent enzyme 5-hydroxyeicosanoid dehydrogenase. It is the only 5-LO product with appreciable chemoattractant activity for human eosinophils. Its actions are mediated by the selective OXE receptor, which is highly expressed on eosinophils, basophils, neutrophils and monocytes. Orthologs of the OXER1 gene, which encodes this receptor, are found in many species except for rodents. Intradermal injection of 5-oxo-ETE into humans and monkeys elicits eosinophil infiltration into the skin, raising the possibility that it may play a pathophysiological role in eosinophilic diseases. To investigate this and possibly identify a novel therapy we sought to prepare synthetic antagonists that could selectively block the OXE receptor. We synthesized a series of indole-based compounds bearing substituents that mimic the regions of 5-oxo-ETE that are required for biological activity, which we modified to reduce metabolism. The most potent of these OXE receptor antagonists is S-Y048, which is a potent inhibitor of 5-oxo-ETE-induced calcium mobilization (IC50, 20 pM) and has a long half-life following oral administration. S-Y048 inhibited allergen-induced eosinophil infiltration into the skin of rhesus monkeys that had been experimentally sensitized to house dust mite and inhibited pulmonary inflammation resulting from challenge with aerosolized allergen. These data provide the first evidence for a pathophysiological role for 5-oxo-ETE in mammals and suggest that potent and selective OXE receptor antagonists such as S-Y048 may be useful therapeutic agents in asthma and other eosinophilic diseases.
Collapse
Affiliation(s)
- William S Powell
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada.
| | - Joshua Rokach
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| |
Collapse
|
4
|
Miller LA, Cossette C, Chourey S, Ye Q, Reddy CN, Rokach J, Powell WS. Inhibition of allergen-induced dermal eosinophilia by an oxoeicosanoid receptor antagonist in non-human primates. Br J Pharmacol 2020; 177:360-371. [PMID: 31655023 PMCID: PMC6989951 DOI: 10.1111/bph.14872] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Revised: 08/13/2019] [Accepted: 08/27/2019] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND AND PURPOSE 5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), acting via the OXE receptor, is unique among 5-lipoxygenase products in its ability to directly induce human eosinophil migration, suggesting its involvement in eosinophilic diseases. To address this hypothesis, we synthesized selective indole-based OXE receptor antagonists. Because rodents lack an OXE receptor orthologue, we sought to determine whether these antagonists could attenuate allergen-induced skin eosinophilia in sensitized monkeys. EXPERIMENTAL APPROACH In a pilot study, cynomolgus monkeys with environmentally acquired sensitivity to Ascaris suum were treated orally with the "first-generation" OXE antagonist 230 prior to intradermal injection of 5-oxo-ETE or Ascaris extract. Eosinophils were evaluated in punch biopsy samples taken 6 or 24 hr later. We subsequently treated captive-bred rhesus monkeys sensitized to house dust mite (HDM) allergen with a more recently developed OXE antagonist, S-Y048, and evaluated its effects on dermal eosinophilia induced by either 5-oxo-ETE or HDM. KEY RESULTS In a pilot experiment, both 5-oxo-ETE and Ascaris extract induced dermal eosinophilia in cynomolgus monkeys, which appeared to be reduced by 230. Subsequently, we found that the related OXE antagonist S-Y048 is a highly potent inhibitor of 5-oxo-ETE-induced activation of rhesus monkey eosinophils in vitro and has a half-life in plasma of about 6 hr after oral administration. S-Y048 significantly inhibited eosinophil infiltration into the skin in response to both intradermally administered 5-oxo-ETE and HDM. CONCLUSIONS AND IMPLICATIONS 5-Oxo-ETE may play an important role in allergen-induced eosinophilia. Blocking its effects with S-Y048 may provide a novel therapeutic approach for eosinophilic diseases.
Collapse
Affiliation(s)
- Lisa A. Miller
- Present address:
California National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
| | - Chantal Cossette
- Meakins‐Christie Laboratories, Centre for Translational BiologyMcGill University Health CentreMontreal, QuebecCanada
| | - Shishir Chourey
- Present address:
California National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFloridaUSA
- Department of Chemical DevelopmentAlbany Molecular Research Inc.Albany, New York
| | - Qiuji Ye
- Present address:
California National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFloridaUSA
- Department of ChemistryRice UniversityHoustonTexas
| | - Chintam Nagendra Reddy
- Present address:
California National Primate Research CenterUniversity of CaliforniaDavisCaliforniaUSA
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFloridaUSA
- Synthetic ChemistryOlon Ricerca Bioscience LLCConcordOhio
| | - Joshua Rokach
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFloridaUSA
| | - William S. Powell
- Meakins‐Christie Laboratories, Centre for Translational BiologyMcGill University Health CentreMontreal, QuebecCanada
| |
Collapse
|
5
|
Ye Q, Chourey S, Reddy CN, Wang R, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys. Br J Pharmacol 2020; 177:388-401. [PMID: 31655025 PMCID: PMC6989946 DOI: 10.1111/bph.14874] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Revised: 08/13/2019] [Accepted: 09/03/2019] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND AND PURPOSE The 5-lipoxygenase product 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (5-oxo-ETE), acting through the OXE receptor, is a potent eosinophil chemoattractant that may be an important proinflammatory mediator in eosinophilic diseases such as asthma. We previously identified a series of indole-based OXE receptor antagonists that rapidly appear in the blood following oral administration but have limited lifetimes. The objective of this study was to increase the potency and plasma half-lives of these compounds and thereby identify the optimal candidate for future preclinical studies in monkeys, as rodents do not have an OXE receptor orthologue. EXPERIMENTAL APPROACH We synthesized a series of substituted phenylalkyl indoles and compared their antagonist potencies, pharmacokinetics, and metabolism to those of our earlier compounds. The potencies of some of their metabolites were also investigated. KEY RESULTS Among the compounds tested, the S-enantiomer of the m-chlorophenyl compound (S-Y048) was the most potent, with an pIC50 of about 10.8 for inhibition of 5-oxo-ETE-induced calcium mobilization in human neutrophils. When administered orally to cynomolgus monkeys, S-Y048 rapidly appeared in the blood and had a half-life in plasma of over 7 hr, considerably longer than any of the other OXE analogues tested. A major hydroxylated metabolite, with a potency close to that of its precursor, was identified in plasma. CONCLUSION AND IMPLICATIONS Because of its highly potent antagonist activity and its long lifetime in vivo, S-Y048 may be a useful anti-inflammatory agent for the treatment of eosinophilic diseases such as asthma, allergic rhinitis, and atopic dermatitis.
Collapse
Affiliation(s)
- Qiuji Ye
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFlorida
- Present address:
Department of ChemistryRice UniversityHoustonTexas
| | - Shishir Chourey
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFlorida
- Present address:
Chemical Development DepartmentAlbany Molecular Research Inc.AlbanyNew York
| | - Chintam Nagendra Reddy
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFlorida
- Present address:
Synthetic ChemistryOlon Ricerca BioscienceConcordOhio
| | - Rui Wang
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFlorida
| | - Chantal Cossette
- Meakins‐Christie Laboratories, Centre for Translational BiologyMcGill University Health CentreMontrealQCCanada
| | - Sylvie Gravel
- Meakins‐Christie Laboratories, Centre for Translational BiologyMcGill University Health CentreMontrealQCCanada
| | - Irina Slobodchikova
- Department of Chemistry and Biochemistry and PERFORM CentreConcordia UniversityMontrealQCCanada
| | - Dajana Vuckovic
- Department of Chemistry and Biochemistry and PERFORM CentreConcordia UniversityMontrealQCCanada
| | - Joshua Rokach
- Claude Pepper Institute and Department of ChemistryFlorida Institute of TechnologyMelbourneFlorida
| | - William S. Powell
- Meakins‐Christie Laboratories, Centre for Translational BiologyMcGill University Health CentreMontrealQCCanada
| |
Collapse
|
6
|
Chourey S, Ye Q, Reddy CN, Wang R, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE). J Med Chem 2018; 61:5934-5948. [PMID: 29972644 DOI: 10.1021/acs.jmedchem.8b00154] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a potent lipid mediator that induces tissue eosinophilia via the selective OXE receptor (OXE-R), which is an attractive therapeutic target in eosinophilic diseases. We previously identified indole OXE-R antagonists that block 5-oxo-ETE-induced primate eosinophil activation. Although these compounds possess good oral absorption, their plasma levels decline rapidly due to extensive oxidation of their hexyl side chain. We have now succeeded in dramatically increasing antagonist potency and resistance to metabolism by replacing the hexyl group with phenylpentyl or phenylhexyl side chains. Compared with our previous lead compound S-230, our most potent antagonist, S-C025, has an IC50 (120 pM) over 80 times lower and a substantially longer plasma half-life. A single major metabolite, which retains antagonist activity (IC50, 690 pM) and has a prolonged lifetime in plasma was observed. These new highly potent OXE-R antagonists may provide a novel strategy for the treatment of eosinophilic disorders like asthma.
Collapse
Affiliation(s)
- Shishir Chourey
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology , 150 West University Boulevard , Melbourne , Florida 32901-6982 , United States
| | - Qiuji Ye
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology , 150 West University Boulevard , Melbourne , Florida 32901-6982 , United States
| | - Chintam Nagendra Reddy
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology , 150 West University Boulevard , Melbourne , Florida 32901-6982 , United States
| | - Rui Wang
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology , 150 West University Boulevard , Melbourne , Florida 32901-6982 , United States
| | - Chantal Cossette
- Meakins-Christie Laboratories, Centre for Translational Biology , McGill University Health Centre , 1001 Decarie Boulevard , Montreal , Quebec H4A 3J1 , Canada
| | - Sylvie Gravel
- Meakins-Christie Laboratories, Centre for Translational Biology , McGill University Health Centre , 1001 Decarie Boulevard , Montreal , Quebec H4A 3J1 , Canada
| | - Irina Slobodchikova
- Department of Chemistry and Biochemistry and PERFORM Centre , Concordia University , 7141 Sherbrooke Street West , Montréal , Quebec H4B 1R6 , Canada
| | - Dajana Vuckovic
- Department of Chemistry and Biochemistry and PERFORM Centre , Concordia University , 7141 Sherbrooke Street West , Montréal , Quebec H4B 1R6 , Canada
| | - Joshua Rokach
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology , 150 West University Boulevard , Melbourne , Florida 32901-6982 , United States
| | - William S Powell
- Meakins-Christie Laboratories, Centre for Translational Biology , McGill University Health Centre , 1001 Decarie Boulevard , Montreal , Quebec H4A 3J1 , Canada
| |
Collapse
|
7
|
Reddy CN, Alhamza H, Chourey S, Ye Q, Gore V, Cossette C, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Metabolism and pharmacokinetics of a potent N-acylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) in rats and monkeys. Eur J Pharm Sci 2018; 115:88-99. [PMID: 29339225 PMCID: PMC10625806 DOI: 10.1016/j.ejps.2018.01.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 01/09/2018] [Accepted: 01/10/2018] [Indexed: 11/26/2022]
Abstract
We previously identified the indole 264 as a potent in vitro antagonist of the human OXE receptor that mediates the actions of the powerful eosinophil chemoattractant 5-oxo-ETE. No antagonists of this receptor are currently commercially available or are being tested in clinical studies. The lack of a rodent ortholog of the OXE receptor has hampered progress in this area because of the unavailability of commonly used mouse or rat animal models. In the present study, we examined the feasibility of using the cynomolgus monkey as an animal model to investigate the efficacy of orally administered 264 in future in vivo studies. We first confirmed that 264 is active in monkeys by showing that it is a potent inhibitor of 5-oxo-ETE-induced actin polymerization and chemotaxis in granulocytes. The major microsomal metabolites of 264 were identified by cochromatography with authentic chemically synthesized standards and LC-MS/MS as its ω2-hydroxy and ω2-oxo derivatives, formed by ω2-oxidation of its hexyl side chain. Small amounts of ω1-oxidation products were also identified. None of these metabolites have substantial antagonist potency. High levels of 264 appeared rapidly in the blood following oral administration to both rats and monkeys, and declined to low levels by 24 h. As with microsomes, its major plasma metabolites in monkeys were ω2-oxidation products. We conclude that the monkey is a suitable animal model to investigate potential therapeutic effects of 264. This, or a related compound with diminished susceptibility to ω2-oxidation, could be a useful therapeutic agent in eosinophilic disorders such as asthma.
Collapse
Affiliation(s)
- Chintam Nagendra Reddy
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Hussam Alhamza
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Shishir Chourey
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Qiuji Ye
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Vivek Gore
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Chantal Cossette
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada
| | - Sylvie Gravel
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada
| | - Irina Slobodchikova
- Department of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke St. W., Montréal, QC H4B 1R6, Canada
| | - Dajana Vuckovic
- Department of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke St. W., Montréal, QC H4B 1R6, Canada
| | - Joshua Rokach
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - William S Powell
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada.
| |
Collapse
|
8
|
Nakamura Y, Ohta T, Oe Y. A Formal anti-Markovnikov Hydroalkoxylation of Allylic Alcohols with a Ruthenium Catalyst. CHEM LETT 2018. [DOI: 10.1246/cl.171104] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Yushi Nakamura
- Department of Biomedical Information, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| | - Tetsuo Ohta
- Department of Biomedical Information, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| | - Yohei Oe
- Department of Biomedical Information, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| |
Collapse
|
9
|
Structure-activity relationship study of β-oxidation resistant indole-based 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) receptor antagonists. Bioorg Med Chem Lett 2017; 27:4770-4776. [PMID: 28943042 DOI: 10.1016/j.bmcl.2017.08.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 08/15/2017] [Accepted: 08/16/2017] [Indexed: 12/13/2022]
Abstract
5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is formed from 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) by the 5-lipoxygenase (5-LO) pathway under conditions associated with oxidative stress. 5-Oxo-ETE is an important pro-inflammatory mediator, which stimulates the migration of eosinophils via a selective G-protein coupled receptor, known as the OXE receptor (OXE-R). Previously, we designed and synthesized structural mimics of 5-oxo-ETE such as 1 using an indole scaffold. In the present work, we added various substituents at C-3 of this moiety to block potential β-oxidation of the 5-oxo-valerate side chain, and investigated the structure-activity relationships of the resulting novel β-oxidation-resistant antagonists. Cyclopropyl and cyclobutyl substituents were well tolerated in this position, but were less potent as the highly active 3S-methyl compound. It seems likely that 3-alkyl substituents can affect the conformation of the 5-oxovalerate side chain containing the critical keto and carboxyl groups, thereby affecting interaction with the OXE-receptor.
Collapse
|
10
|
Chourey S, Ye Q, Reddy CN, Cossette C, Gravel S, Zeller M, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys. Biochem Pharmacol 2017; 138:107-118. [PMID: 28476332 DOI: 10.1016/j.bcp.2017.04.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 04/27/2017] [Indexed: 10/19/2022]
Abstract
We have developed a selective indole antagonist (230) targeting the OXE receptor for the potent eosinophil chemoattractant 5-oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid), that may be useful for the treatment of eosinophilic diseases such as asthma. In previous studies we identified ω2-oxidation of the hexyl side chain of racemic 230 as a major metabolic route in monkeys, but also obtained evidence for another pathway that appeared to involve hydroxylation of the hexyl side chain close to the indole. The present study was designed to investigate the metabolism of the active S-enantiomer of 230 (S230) and to identify the novel hydroxy metabolite and its chirality. Following oral administration, S230 rapidly appeared in the blood along with metabolites formed by a novel and highly stereospecific α-hydroxylation pathway, resulting in the formation of αS-hydroxy-S230. The chirality of α-hydroxy-S230 was determined by the total synthesis of the relevant diastereomers. Of the four possible diastereomers of α-hydroxy-230 only αS-hydroxy-S230 has significant OXE receptor antagonist activity and only this diastereomer was found in significant amounts in blood following oral administration of S230. Other novel metabolites of S230 identified in plasma by LC-MS/MS were αS,ω2-dihydroxy-S230 and glucuronides of S230 and ω2-hydroxy-S230. Thus the alkyl side chain of S230, which is essential for its antagonist activity, is also the major target of the metabolic enzymes that terminate its antagonist activity. Modification of this side chain might result in the development of related antagonists with improved metabolic stability and efficacy.
Collapse
Affiliation(s)
- Shishir Chourey
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Qiuji Ye
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Chintam Nagendra Reddy
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - Chantal Cossette
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada
| | - Sylvie Gravel
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada
| | - Matthias Zeller
- Department of Chemistry, Purdue University, West Lafayette, IN 47906, USA
| | - Irina Slobodchikova
- Department of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke St. W., Montréal, QC H4B 1R6, Canada
| | - Dajana Vuckovic
- Department of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke St. W., Montréal, QC H4B 1R6, Canada
| | - Joshua Rokach
- Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, FL 32901-6982, USA
| | - William S Powell
- Meakins-Christie Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada.
| |
Collapse
|
11
|
Cossette C, Chourey S, Ye Q, Nagendra Reddy C, Gore V, Gravel S, Slobodchikova I, Vuckovic D, Rokach J, Powell WS. Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys. J Med Chem 2016; 59:10127-10146. [DOI: 10.1021/acs.jmedchem.6b00895] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Chantal Cossette
- Meakins-Christie
Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec H4A 3J1, Canada
| | - Shishir Chourey
- Claude
Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901-6982, United States
| | - Qiuji Ye
- Claude
Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901-6982, United States
| | - Chintam Nagendra Reddy
- Claude
Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901-6982, United States
| | - Vivek Gore
- Claude
Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901-6982, United States
| | - Sylvie Gravel
- Meakins-Christie
Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec H4A 3J1, Canada
| | - Irina Slobodchikova
- Department
of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke Street West, Montréal, Quebec H4B 1R6, Canada
| | - Dajana Vuckovic
- Department
of Chemistry and Biochemistry and PERFORM Centre, Concordia University, 7141 Sherbrooke Street West, Montréal, Quebec H4B 1R6, Canada
| | - Joshua Rokach
- Claude
Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 West University Boulevard, Melbourne, Florida 32901-6982, United States
| | - William S. Powell
- Meakins-Christie
Laboratories, Centre for Translational Biology, McGill University Health Centre, 1001 Decarie Boulevard, Montreal, Quebec H4A 3J1, Canada
| |
Collapse
|